Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

Arvinas and Pfizer’s Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.

Ken Song has done it again. The biopharma veteran’s all-out effort to prove T cell engagers’ potential in autoimmune diseases is getting picked up by

In another setback for abortion care in the US, an appeals court has issued an order restricting the distribution of mifepristone through the mail.

Welcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman